SCHEMBL7526215

SCHEMBL7526215

O=C(COCCc1ccccn1)CC(=O)OCCC(c1ccccc1)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
SMN1; SMN2 Q16637 4/20 0.38
LMNA P02545 1/20 0.38
HRH2 P25021 1/20 0.38
TAS1R3 Q7RTX0 1/20 0.38
TAS1R1 Q7RTX1 1/20 0.38
NAAA Q02083 1/20 0.38
NPY1R P25929 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C19 P33261 1/20 0.37
PTPRA P18433 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5406752 0.83 CYP19A1 (0.42) EPHX2SMN1; SMN2LMNAKDM4E
SCHEMBL6924165 0.82 KCNA5 (0.44) CA12CA1CA2CA9NPC1
SCHEMBL5402698 0.80 EPHX2 (0.48) EPHX2SMN1; SMN2LMNACYP1A2CYP2C19
SCHEMBL5401685 0.79 PLA2G4B (0.40) EPHX2
SCHEMBL5407625 0.79 MTNR1A (0.37) EPHX2SMN1; SMN2LMNA
SCHEMBL7530486 0.79 HRH2 (0.40) EPHX2CA12CA1CA2CA9
SCHEMBL7530493 0.79 HRH2 (0.40) EPHX2CA12CA1CA2CA9
SCHEMBL5421203 0.78 MTNR1A (0.36) EPHX2SMN1; SMN2
SCHEMBL5405591 0.78 PTPRA (0.42) EPHX2CA12CA1CA2CA9
SCHEMBL7533696 0.77 SMN1; SMN2 (0.47) NPC1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020147222-A1 Dihydropyridine derivatives AJINOMOTO CO. INC (JP) 2002-10-10 US disclosed
EP-1191021-A1 DIHYDROPYRIDINE DERIVATIVE Ajinomoto Co., Inc. (JP) 2002-03-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020147222-A1 Dihydropyridine derivatives CACNA1B, CACNA1D, CACNA1C EPHX2 3229/4885CA12 4539/4885CA1 1424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.